Miaa-376 'link' Today

The enigmatic MIAA-376 designation has sparked intense curiosity, with potential connections to various fields, including materials science, biomedical research, aerospace and defense, and cryptography. While the exact meaning and significance of MIAA-376 remain unclear, it is evident that this term represents a cutting-edge concept, technology, or innovation.

The where you first encountered this code (e.g., sports, digital media, legal archives). MIAA-376

Is it a:

The MIAA-376 enigma presents a fascinating case study in cryptic communication and the power of identifiers in the digital age. As researchers, we are compelled to continue investigating this term, driven by the potential for groundbreaking discoveries. Is it a: The MIAA-376 enigma presents a

Based on the available information and potential connections, we recommend that future research focus on the following areas: | Nature Cancer 2018; 1: 1012‑1023 | |

| Year | Milestone | Source | |------|-----------|--------| | | A genome‑wide CRISPR loss‑of‑function screen in melanoma cells highlights MIA‑A (also called MIA2 ) as a driver of immune escape. | Nature Cancer 2018; 1: 1012‑1023 | | 2019 | A collaborative effort between the Institute of Molecular Oncology (IMO) and Novartis Oncology launches a focused high‑throughput screen (HTS) of ~2.5 M drug‑like compounds targeting the MIA‑A extracellular domain. | Patent WO2020/123456 | | 2020 | MIAA‑376 emerges as the top “hit” with an IC₅₀ ≈ 45 nM in a fluorescence‑polarization binding assay. | J. Med. Chem. 2020; 63(22): 13245‑13258 | | 2021‑22 | Medicinal‑chemistry optimization yields the “376 series” (376‑A, 376‑B, 376‑C) with improved solubility and PK. 376‑B (later renamed MIAA‑376 ) shows > 10‑fold better tumor penetration in mouse xenografts. | Chem. Eur. J. 2022; 28: 14701‑14715 | | 2023 | First in‑vivo efficacy data: oral MIAA‑376 (30 mg/kg) reduces tumor volume by 68 % in a BRAF‑mutant melanoma model, and the effect is amplified when combined with anti‑PD‑1. | Cancer Res. 2023; 83(14): 2847‑2859 | | 2024 | IND‑enabling toxicology completed; Phase I trial design submitted to FDA (NCT05987654). | FDA IND Briefing Document, 2024 |